Insurance coverage of blockbuster obesity drugs has been spotty at best over the years, and it looks like things are getting worse, not better. Plans are dropping coverage or restricting it further.
Copyright 2026 NPR
Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.